Scarica l'app Stockscreener
0.4557
3.57%
0.0157
Dopo l'orario di chiusura:
.46
0.0043
+0.94%
Ensysce Biosciences Inc Borsa (ENSC) Ultime notizie
An FDA hearing on psychedelic drugs is set for Sept. 14. Ensysce will take part. - Stock Titan
Ensysce completes PF614-MPAR-102 clinical enrollment - grafa.com
Ensysce completes enrollment in opioid overdose study By Investing.com - Investing.com Australia
An opioid study from Ensysce is fully enrolled to test overdose protection - Stock Titan
Ensysce Faces Nasdaq Delisting Risk After Cy Biopharma Deal Triggers Change of Control - Minichart
Ensysce Biosciences raises $21M in initial tranche, meets Nasdaq equity rules, seeks second bid-price grace period - tradingview.com
Ensysce (ENSC) completes private raise with contingent proceeds - Stock Titan
Ensysce (ENSC) Results Versus Estimates: The Bottom-Line Figure Beats Its Comparison in the Latest Reading; After Earnings: The Stock Ends Down 3.87% for the Current SessionEarnings Yield Spread - vinanet.vn
Ensysce (ENSC) chair boosts stake, locks in votes on merger - Stock Titan
ENSC: Acquisition and financing position CY200 for CRPS advancement, extending cash runway to 2027 - TradingView
ENSC: Acquisition and financing position CY200 for Phase II CRPS trial and long-term pipeline growth - TradingView
Ensysce Biosciences director Gower buys $444,169 in company stock - Investing.com
Ensysce Biosciences Insider Bought Shares Worth $444,169, According to a Recent SEC Filing - marketscreener.com
Ensysce Biosciences (ENSC) director buys stock and converts debt - Stock Titan
Ensysce Biosciences earnings beat by $0.51, revenue fell short of estimates - Investing.com Canada
MSN Money - MSN
Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma
Ensysce Completes Cy Biopharma Acquisition Adding Lead CRPS Candidate - Minichart
Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com - Investing.com Australia
Ensysce Q2 EPS beats; completes Cy Biopharma acquisition for $38.6m - scanx.trade
Ensysce Biosciences (ENSC) widens loss as cash falls, adds funding via Cy Biopharma deal - Stock Titan
Ensysce Biosciences Q2 net loss widens on higher R&D costs - TradingView
ENSC: Acquisition and new funding extend cash runway, with clinical pipeline and losses both increasing - TradingView
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - FinancialContent
ENSC Q1 2026 Earnings: Narrower-than-Expected Loss Marks 30% Beat Amid Persistent Share Weakness - vinanet.vn
Cy Biopharma merges with Ensysce Biosciences - Startupticker.ch
Ensysce Biosciences (ENSC) officer reports 154.8M underlying common via preferred - Stock Titan
Ensysce Biosciences Acquires Cy Biopharma to Expand Pain Pipeline - sekbernews.id
Ensysce Biosciences Inc (NASDAQ: ENSC) Share Price, ENSC Stock News, ENSC Share Price & Updates - Kalkine
Orrick Advises Cy Biopharma on Acquisition by Ensysce Biosciences and up to $77 Million Private Financing - orrick.com
Ensysce Biosciences Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
Form 8K Ensysce Biosciences Inc For: 6 August By Investing.com - Investing.com South Africa
Ensysce Biosciences (ENSC) Drifts Lower as Shares Test Support Near $0.49Last Point Resistance - vinanet.vn
Ensysce completes Cy Biopharma acquisition, raises $21.5 million By Investing.com - Investing.com Australia
Ensysce Biosciences Acquires Cy Biopharma in Deal Backed by Up to $77 Million Financing - citybiz
Thursday's session: most active stocks - ChartMill
Ensysce Biosciences completes acquisition of Cy Biopharma - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Ensysce expands into neuroplastogenic pain with USD 77m Cy Biopharma acquisition - AllSci
Ensysce Biosciences Surges After Cy Biopharma Acquisition and Large Financing Package - Quiver Quantitative
Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing - Yahoo Finance
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Ensysce completes Cy Biopharma acquisition, raises $21.5 million - Investing.com
Ensysce Acquires Cy Biopharma, Expands Pain Therapy Portfolio - TipRanks
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Ensysce Biosciences (ENSC) Dips 3.18% to $0.37, Nearing Critical Support ZonePost-Earnings Moves - dars.gov.et
The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch - Barchart.com
Ensysce Biosciences (NASDAQ:ENSC) surges 48%, still faces 141% climb for Nasdaq $1 threshold - TechStock²
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why is Ensysce Biosciences stock surging today? By Investing.com - Investing.com Canada
Why is Ensysce Biosciences stock surging today? - Investing.com
12 Health Care Stocks Moving In Monday's After-Market SessionEnsysce Biosciences (NASDAQ:ENSC), TransC - Benzinga
Ensysce lands $5.3M grant, completing $15.1M NIDA opioid-safety award - Dealroom
ENSC Q1 2026 Earnings: EPS Beat of 30.16% Highlights Cost Discipline Amid Pre-Revenue PipelineQuarterly Earnings Report - vinanet.vn
Ensysce Biosciences Inc (ENSC) Institutional Confidence - TradingKey
Ensysce Biosciences (ENSC) Edges Higher as Shares Test Key Resistance at $0.27Trend Following Picks - vinanet.vn
Ensysce Biosciences Inc (ENSC) Cash Flow - TradingKey
ENSC|Ensysce Biosciences Inc|Price:0.255|Chg%:-0.006 - TradingKey
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):